Kura Oncology, Inc. $KURA Shares Bought by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB grew its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 78.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 872,000 shares of the company’s stock after purchasing an additional 382,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Kura Oncology were worth $9,060,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of KURA. Vanguard Group Inc. boosted its stake in shares of Kura Oncology by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company’s stock valued at $57,224,000 after purchasing an additional 39,105 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in Kura Oncology by 101.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock worth $19,688,000 after buying an additional 1,121,228 shares during the period. Qube Research & Technologies Ltd increased its stake in Kura Oncology by 63.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock worth $11,032,000 after buying an additional 738,761 shares during the period. Renaissance Technologies LLC lifted its holdings in Kura Oncology by 111.6% in the 4th quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock worth $19,020,000 after buying an additional 965,256 shares in the last quarter. Finally, UBS Group AG lifted its holdings in Kura Oncology by 118.3% in the 4th quarter. UBS Group AG now owns 1,060,025 shares of the company’s stock worth $11,014,000 after buying an additional 574,455 shares in the last quarter.

Wall Street Analyst Weigh In

KURA has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research report on Tuesday, April 21st. Jefferies Financial Group set a $24.00 price target on Kura Oncology in a research note on Thursday, May 28th. Mizuho cut their price target on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 24th. Wall Street Zen upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 4th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and an average target price of $25.58.

Kura Oncology Trading Up 2.1%

NASDAQ:KURA opened at $9.05 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.14 and a current ratio of 6.15. Kura Oncology, Inc. has a one year low of $5.45 and a one year high of $12.49. The business’s 50-day simple moving average is $9.31 and its 200 day simple moving average is $9.33. The stock has a market cap of $803.37 million, a price-to-earnings ratio of -2.70 and a beta of 0.36.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The firm had revenue of $18.27 million for the quarter, compared to analysts’ expectations of $25.97 million. As a group, sell-side analysts predict that Kura Oncology, Inc. will post -3.47 earnings per share for the current fiscal year.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.